Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALF-5755 in non-acetaminophen severe acute hepatitis and early acute liver failure
2010-020657-14Phase 2Completed
- Sponsor
- Alfact Innovation SAS
- Start
- Mar 2011
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in fulminant hepatitis and acute hepatitis comparing ALF-5755 with Placebo (2 arms). Primary endpoint: Rate of change of prothrombin ratio (PR). Started Mar 2011; status: completed.
02
Drugs
ALF-5755
03
Conditions
fulminant hepatitisacute hepatitis
Beyond the preview
Go deeper on 2010-020657-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020657-14.